Correction: Continuing a cancer treatment despite tumor growth may be valuable: Sunitinib in renal cell carcinoma as example (PLoS ONE (2014) 9, 5 (e96316) DOI: 10.1371/journal.pone.0096316);Continuing a cancer treatment despite tumor growth may be valuable: Sunitinib in renal cell carcinoma as example

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Burotto, Mauricio ^a   Wilkerson, Julia ^a   Stein, Wilfred ^a,b   Motzer, Robert ^c   Bates, Susan ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON; SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TREATMENT DURATION; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; KIDNEY TUMOR; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; HUMANS; INDOLES; KIDNEY NEOPLASMS; PYRROLES; TREATMENT OUTCOME;

EID: 84900436763     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105179     Document Type: Erratum

References (26)

1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134. (Pubitemid 46089673)
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124. (Pubitemid 46089672)
3. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281. (Pubitemid 46849157)
4. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111. (Pubitemid 350296300)
5. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
6. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, et al. (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061-1068.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
8. Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, et al. (2008) Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist 13: 1046-1054.
9. Stein WD, Yang J, Bates SE, Fojo T (2008) Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist 13: 1055-1062.
10. Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, et al. (2011) Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17: 907-917.
11. Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, et al. (2012) Analyzing the pivotal trial that compared sunitinib and IFN-alpha in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res 18: 2374-2381.
12. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
13. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, et al. (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931-1939.
14. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, et al. (2013) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14: 552-562.
15. Korn RL, Crowley JJ (2013) Overview: progression-free survival as an endpoint in clinical trials with solid tumors. Clin Cancer Res 19: 2607-2612.
16. Villaruz LC, Socinski MA (2013) The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement. Clin Cancer Res 19: 2629-2636.
17. Fojo AT, Noonan A (2012) Why RECIST works and why it should stay - counterpoint. Cancer Res 72: 5151-5157; discussion 5158.
18. Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, et al. (2012) When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 104: 1534-1541.
19. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, et al. (2010) Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28: 357-360.
20. Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, et al. (2013) Planning cancer control in Latin America and the Caribbean. Lancet Oncol 14: 391-436.
21. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, et al. (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26: 5326-5334.
22. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, et al. (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 27: 1999-2006.
23. Goldberg SB, Oxnard GR, Digumarthy S, Muzikansky A, Jackman DM, et al. (2013) Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. Oncologist 18: 1214-1220.
24. Ou SH, Janne PA, Bartlett CH, Tang Y, Kim DW, et al. (2014) Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 25: 415-422.
25. Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, et al. (2013) Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 14: 1175-1182.
26. Calvo E, Escudier B, Motzer RJ, Oudard S, Hutson TE, et al. (2012) Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48: 333-339.